After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. He earned his MS in Bioinformatics from Boston University. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. in Anthropology and Natural Sciences and an M.S. He oversees the firm's financial functions, including middle office operations, accounting, valuation, tax and financial reporting. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Our website uses cookies to distinguish you from other users of our website. Harvey is a Controller at RA Capital Management. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University. In his career, Scott has worked to raise over $600 million in funding for ventures with which he has been directly involved as a founder or operating executive. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Prior to RA Capital, he represented emerging companies and venture capital investment funds at two international law firms. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Pieter holds a BA from Trinity College and a JD from Yale Law School. Kate previously served as Health Law Assistant at Mintz. Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Prior to RA, he served in a dual role at Merck Research Laboratories (MRL). Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. Prior to RA, Elena gained analyst and research experience through roles with Alira Health, Mandarin Capital Partners, LifeLineLab S.r.l. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Laura is an Executive Assistant at RA Capital Management. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. in Life Science from National Taiwan University, M.S. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Adisons primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Ryan Russell is a Fund Accountant at RA Capital Management. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Find Peter Kolchinsky's contact information, phone numbers, home addresses, age, background check, white pages, resumes and CV, places of employment, social media profiles, photos and videos, public records, arrest records, work history, news and business records . Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Megan has a BS in Microbiology & Cell Science from University of Florida. in Business Administration in Management Information Systems from Northeastern University. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. From 1990- 1997, he held investment, business development, R&D, and marketing positions at DuPont Ventures. Prithviraj comes to RA from CVS Health, where he was Director of HealthHUB Product Technology Strategy and Enablement. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. Meredith is a Senior Research Assistant at RA Capital Management. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Max has a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan. Jenna previously held roles as Senior Medical Writer and Analyst at Costello Medical Consulting. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. At Prevail, Emily led business functions including business development, strategy, commercialization, public relations, patient advocacy, and intellectual property, and co-led financings generating $250 million in proceeds, including the companys IPO in 2019. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. Matt Beverly is a Senior Software Engineer at RA Capital Management. Prior to co-founding Therapeutics Alliances, Nadim worked in NYUs Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Prior to MP, she was a Consultant at Clarion Healthcare. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Prior to this, Gerald was Director of Scientific Operations for RA Capital. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Shannon is a Receptionist and Facilities Administrator at RA Capital Management. Before Energetic, she was Head of Carbon Strategic Partnerships at Indigo Ag, where she led external innovation focused on solutions that minimize or sequester agricultural GHG emissions and deliver additional environmental, social, and economic co-benefits. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (acquired by Sterling Pharma Solutions). Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Emily Greenis a Visual Identity Designer at RA Capital Management. and Ultragenyx Pharmaceuticals. He holds a MS from Northeastern University and a BA from Hamilton College. Prior to GHP, Lorena served as an Assurance Senior at EY. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Prior to joining RA, Kathryn was SVP of Strategy at Energetic Insurance where she addressed regulatory-driven commercial lender limitations to enable financing for renewable energy and efficiency via financial insurance products. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. In this position, he played a critical role in building Mercks oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. Eric previously served as Director, Chief Risk and Compliance Officer, Americas at Aberdeen Asset Management. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Le Ho is a Business Systems Analyst at RA Capital Management. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Previously, Shan Shan covered Orphan Heme, Orphan GOF, Vaccines, and various Gene Therapies as a Senior Associate. Most importantly, this book describes concrete . She also has a Master's in Accounting from Boston College and is a CPA. Josh Resnick is a Senior Managing Director at RA Capital Management. Walter has a BS in Biology from Davidson College and a MS in Genetics from University of Georgia. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. She has published over fifty papers in peer reviewed journals. Previously, Jake covered solid tumor oncology landscapes. Henry has a BA in Biology & Economics from Dartmouth College. Prior to Merck, he was a Partner with the Partners Innovation Fund, the corporate venture arm of Mass General Brigham hospital (formerly Partners HealthCare), where he invested in Seed/Series A therapeutics-focused companies. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. Michael Sherman is a Venture Partner at RA Ventures. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. Maryann received her Bachelor of Science in English from Northeastern University. She has spent the last five years as a Senior Finance Associate at Great Hill Partners. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. from Yale and practiced as a cardiac anesthesiologist. Support. She is a CPA. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Sophie is a Fellow of the Royal College of Physicians, London, UK. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Prior to this, Cosmas was a Director at Takeda Pharmaceuticals where he was responsible for developing multiple partnerships and platforms on emerging technologies, along with leading drug development teams in cell and gene therapies. Harveys primary responsibility is to oversee all accounting related activities for the firm. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Jenna Hebert is an Associate within the TechAtlas division of RA Capital Management. Copyright 2023 Surperformance. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Michael Ryan is an EIR at RA Capital. He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Jenna has a B.A. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. in Mechanical & Aerospace Engineering from Sharif University of Technology, Tehran, Iran and a PhD in Molecular Engineering from Pritzker School of Molecular Engineering, University of Chicago. David Migl is an Analyst on the Investment Team at RA Capital Management. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. The film delves into the psychological roots of Hook's anger, Peter Pan's everlasting childhood, and Wendy's reluctance to face adulthood. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. She received a BA from Princeton University and an MBA from Harvard Business School. Tom has more than nine years of operations experience. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Phi previously worked as an Executive Assistant at Relay Therapeutics. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. She worked previously in desktop publishing and as a freelance designer. Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. James is admitted to practice law in the Commonwealth of Massachusetts. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Tom Thomas is an Associate with the TechAtlas division of RA Capital Management. Let us know if you like it and we may post more pieces with this option.) Not so long ago, his mother and father were not rich. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University.
Most Annoying Email Newsletters To Sign Up For, Henry Cavill Personal Assistant, Worst Nursing Homes In Massachusetts, Is Trevor Rogers Related To Taylor Rogers, Darpa D Wave Mind Control, Articles P